LEADER : Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

LEADER : Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

• FDA approved for reduction of cardiac mortality in adults with T2DM and established CVD.

• Liraglutide is a suggested add-on therapy to metformin for T2DM patients with established CVD (AACE 2019).

Infographic

Reference

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22.

About the author 

MyEndoConsult

The MyEndoconsult Team. A group of physicians dedicated to endocrinology and internal medicine education.

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}

Pathophysiology Videos


Videos

  • Learn Basic Physiology
  • Pathophysiology (Advanced Concepts)
  • Clinical Correlates
>